- Home
- DNLI vs NAMS Comparison
DNLI vs NAMS Comparison
Compare DNLI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | NAMS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | DNLI | NAMS |
|---|---|---|
| Price | $25.83 | $34.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $34.33 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $408.85 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.58 | $20.53 |
| 52 Week High | $26.80 | $42.21 |
Technical Indicators
Market Signals| Indicator | DNLI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 74.24 | 61.14 |
| Support Level | $18.07 | $33.83 |
| Resistance Level | N/A | $37.27 |
| Average True Range (ATR) | 1.15 | 1.53 |
| MACD | 0.24 | 0.57 |
| Stochastic Oscillator | 83.50 | 79.16 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.